Background: Anti-tumorigenic vs pro-tumorigenic roles of estrogen receptor-beta (ESR2) in breast cancer remain unsettled. We investigated the potential of TP53 status to be a determinant of the bi-faceted role of ESR2 and associated therapeutic implications for triple negative breast cancer (TNBC). Methods: ESR2-TP53 interaction was analyzed with multiple assays including the in situ proximity ligation assay. Transcriptional effects on TP53-target genes and cell proliferation in response to knocking down or overexpressing ESR2 were determined. Patient survival according to ESR2 expression levels and TP53 mutation status was analyzed in the basal-like TNBC subgroup in the Molecular Taxonomy of Breast Cancer International Consortium (n ¼ 308) and Roswell Park Comprehensive Cancer Center (n ¼ 46) patient cohorts by univariate Cox regression and log-rank test. All statistical tests are two-sided. Results: ESR2 interaction with wild-type and mutant TP53 caused pro-proliferative and anti-proliferative effects, respectively. Depleting ESR2 in cells expressing wild-type TP53 resulted in increased expression of TP53-target genes CDKN1A (control group mean [ , P ¼ .008) was decreased in cells expressing mutant TP53. Overexpressing ESR2 had opposite effects. Tamoxifen increased ESR2-mutant TP53 interaction, leading to reactivation of TP73 and apoptosis. High levels of ESR2 expression in mutant TP53-expressing basal-like tumors is associated with better prognosis (Molecular Taxonomy of Breast Cancer International Consortium cohort: log-rank P ¼ .001; hazard ratio ¼ 0.26, 95% confidence interval ¼ 0.08 to 0.84, univariate Cox P ¼ .02). Conclusions: TP53 status is a determinant of the functional duality of ESR2. Our study suggests that ESR2-mutant TP53 combination prognosticates survival in TNBC revealing a novel strategy to stratify TNBC for therapeutic intervention potentially by repurposing tamoxifen.
tumors. This, coupled with the long-term ineffectiveness of cytotoxic chemotherapy, makes it urgent to discover new therapeutic targets and strategies to treat TNBC. Although ESR1 is not expressed, ESR2 is expressed in about 60%-80% of TNBC (1) (2) (3) . Furthermore, unlike luminal BCs where TP53 is wild type (WT) in the majority of cases, TP53 is mutated in about 80% of TNBC (4-6). ESR1's role as a pro-tumorigenic factor in BC is well established, and our studies have shown that ESR1 is capable of binding and functionally inactivating WT TP53 in luminal BC (7) (8) (9) (10) . ESR1-TP53 crosstalk resulting in cooperation (11) or antagonism (12) has also been reported. However, the role of ESR2 in BC has been elusive (13, 14) . Although an anti-proliferative role for ESR2 has been proposed primarily based on overexpression of exogenous ESR2 cDNA in cancer cell lines (15) (16) (17) , including overexpression in a TNBC cell line to show antagonism toward mutant TP53 (18, 19) , data from other studies do not fit this paradigm. For example, treatment of ovariectomized mice with an ESR2-specific agonist resulted in increased cell proliferation to a similar extent that was observed upon treatment with 17b-estradiol (20) . Further, markers of cell proliferation co-localize with ESR2 in mammary epithelial cells (21) and in TNBC (22) . Both of these observations are inconsistent with an anti-proliferative role for ESR2. More recently, ESR2 has been shown to have a pro-proliferative role in BC stem cells (23) . On the other hand, ESR2 is reported to alleviate the inhibitory effect of ESR1 on TP53-mediated transcriptional regulation (24) . Although some retrospective studies on BC tissues showed that ESR2 is an indicator of favorable prognosis (25) (26) (27) (28) (29) (30) (31) , pro-tumorigenic functions of ESR2 were observed in other studies (32) (33) (34) (35) (36) . Only some of these divergent effects could be attributed to expression of specific isoforms and their cellular location (37) . Such inconsistent observations suggest that ESR2 may have bi-faceted functions depending on the cellular context (1, 13, 38, 39) . However, the mechanisms underlying such bi-faceted functions of ESR2 remain unknown.
Somatic mutations in TP53 are very frequent and are clonally dominant compared with other genes in TNBC (5, 40) . In addition to losing tumor suppressor properties and exerting dominant-negative regulation over any remaining WT TP53, certain mutant TP53s are known to acquire oncogenic gain-offunction properties. Cellular functions mediated by mutant TP53 are context dependent and include increased invasiveness, angiogenesis, abnormal epigenetic regulation, enhancement of "stemness," and therapeutic resistance (41) (42) (43) (44) (45) (46) (47) (48) (49) . In this study, we have analyzed the interaction between ESR2 and TP53 signaling and addressed whether TP53 status could be a determinant of pro-vs anti-proliferative functions of ESR2 affecting clinical outcome in basal-like TNBC patients.
Methods

Proximity Ligation Assay (PLA)
PLA is a sensitive and specific in situ protein-protein interaction assay where signals generated by primary and secondary antibodies are amplified by rolling circle replication of circular DNA generated by antibody-liked oligonucleotides, followed by fluorescent labeling to produce punctate fluorescent dots (50) . PLA was performed using the Duolink II (Olink Bioscience)/ MilliporeSigma reagents and protocol.
Immunohistochemical Staining and Scoring of the Human BC Tissue Micro Array (TMA)
TMAs were constructed using three 1-mm tissue cores (triplicates) from tumor specimens and controls from eligible patients who had surgeries performed between 1995 and 2008 at Roswell Park Comprehensive Cancer Center (Roswell), Buffalo, NY. Appropriate Institutional Review Board approval consistent with federal, state, and local requirements was obtained for this project. The TMAs used in this study were generated from preexisting paraffin blocks, and as per the Institutional Review Board they are "exempt" because they contain no patient identifiers. After staining with TP53 and ESR2 antibodies, TMA slides were digitally scanned using Aperio Scanscope (Aperio Technologies, Inc., Vista, CA), and nuclear ESR2 and TP53 immunohistochemistry (IHC) signals were quantitatively scored. The high or low expression classification was determined by the median of the observed patient-tumor IHC H-scores.
Analysis of Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) Data
METABRIC clinical data including survival data, mRNA expression data, TP53 mutation status, and PAM50 subtype information were previously published (4, 40) and downloaded from www.cbioportal.org. Overall survival and BC-specific survival (BCSS), defined as the time of diagnosis to the time of a BCrelated death, were used for the survival analyses in the basallike subgroup (n ¼ 308).
Statistical Analyses
All P values are interpreted as described in the 2016 ASA P Value Statement (51) . Statistical significance of comparison of relative gene expression, cell growth, cell cycle, and apoptosis assays was determined by Student t test. Statistical significance of BCSS from METABRIC was tested using univariate Cox analysis (treating ESR2 log 2 expression values as a continuous variable) or log-rank test (defining two or three patient groups according to low or high ESR2 expression). All statistical tests were twosided. P values less than .05 were deemed statistically significant throughout, with no adjustment for multiplicity.
Detailed Methods are in the Supplementary Materials (available online).
Results
Direct Interaction of ESR2 With Both WT and Mutant TP53
We have demonstrated ESR2 binds directly to TP53 (52, 53) , and this finding was subsequently confirmed in an independent study (19) . PLA (50) showed that ESR2 is in complex with WT TP53 in situ in MCF-7, ZR-75-1 (luminal BC cells), and CAL-51 online). Co-IP assays further confirmed the specific interaction of endogenous mutant and WT TP53 with the endogenous ESR2 and the exogenously expressed FLAG-ESR2 ( Figure 1G -K).
Reciprocal cell-free Glutathie S-Transferase-pull down assays showed that the region of ESR2 containing the C and D domains (amino acid residues: 149-248) was necessary and sufficient to bind to TP53, whereas the C-terminal regulatory domain of TP53 (amino acid residues: 361-393) was the minimal region required for interaction with ESR2 ( Figure 1 , L and M, and Supplementary Figure 3A -E, available online). Collectively, these protein-protein interaction data demonstrate that ESR2 and TP53 are found in one complex and are capable of binding directly to one another.
Effect of ESR2 on TP53-Target Gene Expression and Cell Proliferation in the WT TP53 Context
We hypothesized that the direct protein-protein interaction between ESR2 and WT TP53 might inhibit TP53's function as a transcriptional regulator. First, we confirmed with quantitative realtime polymerase chain reaction and immunoblotting that ESR2 is expressed in measurable levels in multiple BC cell lines expressing either WT TP53 or mutant TP53 and can be reproducibly knocked down with multiple RNAi approaches and be overexpressed (Supplementary Figure 4A -E, available online). Upon silencing ESR2 expression in MCF-7 cells, the mRNA levels of CDKN1A (p21), BBC3 (PUMA), and PMAIP1 (NOXA) (genes activated by TP53) were induced, whereas the levels of Opposite effects on transcript levels were observed when ESR2 was overexpressed in these cells ( Figure 2F , I, J). These data show that endogenous ESR2 is capable of blocking both the transcriptional activation and repression by TP53.
Quantitative chromatin immunoprecipitation (qChIP) assays showed that knocking down of ESR2 in MCF-7 cells resulted in enhanced TP53 recruitment to CDKN1A and BBC3 promoters ( Figure 2C ), resulting in their increased expression ( Figure 2D ). On the contrary, there was three-to four-fold reduction in TP53 recruitment to these promoters following overexpression of FLAG-tagged-ESR2 or HA-tagged ESR2 ( Figure 2E ; Supplementary Figure 5A , available online, respectively) and concomitant reduction in CDKN1A and BBC3 protein levels ( Figure 2F ).
Consistent with the repressive effect of ESR2 on TP53 transcriptional targets, induction of ESR2 knockdown resulted in increased apoptosis in MCF-7 compared with control cells ( Figure 3A ) and levels of pro-apoptotic proteins such as BAX, uncleaved and cleaved BID, BCL2L11/BIM, and cleaved poly (ADPribose) polymerase (PARP1) were increased ( Figure 3B Furthermore, cell cycle arrest in the G1-phase was increased, whereas the S-phase was decreased when ESR2 expression was silenced in MCF-7 and CAL-51 ( Figure 3 , E and F). Colony formation assays showed that cell proliferation was considerably reduced in ESR2-knocked down cells ( Figure 3G ). Collectively, these data show that ESR2 has a pro-proliferative effect in BC cells expressing WT TP53 ( Figure 3H ).
Effect of ESR2 on TP53-Target Gene Expression and Cell Proliferation in the Mutant TP53 Context
Unlike in the case of BC cells expressing WT TP53 where increased expression of TP53-target genes CDKN1A (control group Unlike in the parental MDA-MB-231 cells ( Figure 5A ), ESR2 depletion did not have a statistically significant effect on transcription of TP53-target genes in TP53KO cells ( Figure 5B ). When the isogenic TP53KO cells were transfected with WT TP53 cDNA, transcription of both CDKN1A and BBC3 ( Figure 5C ) was increased, and when ESR2 was depleted, there was further increase in these transcripts, reminiscent of luminal BC cells expressing endogenous WT TP53. Knocking down ESR2 in either null-TP53 or WT TP53 cells did not affect TP53 protein levels (Supplementary Figure 6C , available online), ruling out the possibility that changes in TP53 levels caused by ESR2 depletion could have contributed to the ESR2-mediated effects on transcription of CDKN1A and BBC3.
Compared with MDA-MB-231, the BC3 TNBC cell line expressing endogenous WT TP53 (BC3-WT TP53) (54, 55) showed complementary response to manipulating ESR2 levels (depletion vs overexpression) ( Figure 5 , D and E). Furthermore, similar to the isogenic MDA-MB-231-TP53KO cells, isogenic BC3-shTP53 cell line where WT TP53 was stably depleted did not show any effect on TP53-target gene expression when ESR2 was depleted ( Figure 5F ). Moreover, CAL-51 cells the showed similar effects as observed in BC3-WT TP53 cells ( Figure 5G ). These data show that ESR2 is pro-proliferative in TNBC cells expressing WT TP53 and anti-proliferative in those expressing mutant TP53. Both of these effects are TP53 dependent. One of the major tumorigenic gain-of-functions of mutant TP53 is its ability to bind and inactivate tumor suppressor TP73, a member of the TP53 family ( Figure 6A ) (49, (56) (57) (58) (59) (60) (61) (62) . CDKN1A, BBC3, and PMAIP1 have been reported to be transcriptional targets of TP73 (63) (64) (65) (66) . Because TP73 deregulation is a frequent event in BC (67) (68) (69) and is expressed in MDA-MB-231 cells (70), we hypothesized that ESR2 may sequester and prevent mutant TP53 from binding and inhibiting tumor suppressor TP73, leading to TP73 activation and its enhanced recruitment to TP53/ TP73-target gene promoters. PLA showed interaction between endogenous TP73 and mutant TP53 in MDA-MB-231, MDA-MB-468, and SK-BR-3 cells, and the interaction was increased when ESR2 was depleted ( Figure 6B , G, and I) whereas the opposite was observed in ESR2-overexpressing cells (Supplementary Figure 7, A and B, available online) . Furthermore, coimmunoprecipitation assay showed that TP73 binding to mutant TP53 was increased in ESR2-depleted cells (Figure 6C Figure 8A -C, available online). The ability of ESR2 to discriminate between mutant TP53 and TP73 for binding could be a result of the lack of conservation in TP73 of the carboxy-terminal domain of TP53 (71,72) ( Figure 6A ) because this domain is minimally required for binding to ESR2 ( Figure 1L; Supplementary Figure 3 , D and E, available online). Indeed, qChIP assays showed that TP73 recruitment to CDKN1A and BBC3 promoters in MDA-MB-231 cells is decreased when ESR2 was depleted ( Figure 6D ). Consistent with these observations, depleting TP73 decreased transcription of TP53 target genes ( Figure 6E, F, H ). These data demonstrate that by sequestering mutant TP53, ESR2 derepresses TP73, leading to increased expression of its target genes that are anti-tumorigenic ( Figure 6J ).
Effect of Tamoxifen on ESR2-Mutant TP53 Interaction and TP73 Activity
Tamoxifen is a competitive inhibitor of ESR1 and is widely used to treat ESR1-positive BC (73, 74) , whereas it is not standard-ofcare for TNBC. However, there have been isolated reports on beneficial effects of tamoxifen therapy in certain cohorts of ESR1-negative BC. It has been reported that high levels of ESR2 in ESR1-negative BC (28) and TNBC (25) patient tumors were associated with good clinical outcome in response to tamoxifen therapy. In another study, expression of ESR2 along with its coregulator was found to be predictive for benefit from tamoxifen therapy (75) . Furthermore, fulvestrant was reported to synergize with tamoxifen to upregulate ESR2 in BC cells (76) , and ESR2 enhanced the sensitivity of ESR1-positive BC cells to the antiestrogenic effects of endoxifen, a metabolite of tamoxifen (77) . However, the mechanistic basis for such beneficial effects of tamoxifen in TNBC remains undefined. Here, we show that, surprisingly, treatment with 4-hydroxy tamoxifen leads to increased ESR2-mutant TP53 interaction in MDA-MB-231, MDA-MB-468, and SK-BR-3 cells ( Figure 7A , C, and D, respectively). Concomitantly, there was decreased mutant TP53-TP73 interaction ( Figure 7B ), which in turn led to enhanced recruitment of TP73 to the PUMA gene promoter (Supplementary Figure 9A , available online). ESR2 protein levels were increased after tamoxifen treatment (Figure 7, E and H) . Importantly, tamoxifen failed to enhance transcription of CDKN1A and BBC3 in the absence of ESR2 or TP73 in MDA-MB-231 cells (Figure 7, F and G) , MDA-MB-468 ( Figure 7 , I and J) and SK-BR-3 cells (Supplementary Figure 9 , B and C, available online).
Impact of TP53 Status on the Prognostic Role of ESR2 in Patients with Basal-like TNBC Tumors
As in the case of TNBC cell lines, TP53 and ESR2 protein expression (IHC) and their interaction (PLA) were observed in representative TNBC tumor tissues ( Figure 8A ). To confirm the findings from the in vitro experiments with cell lines, we analyzed data from 308 patients with basal-like tumors in the METABRIC cohort of 1904 BC patients (4, 6, 40) . In the mutant analysis TP53 subgroup of the basal-like tumors (n ¼ 259), low levels of ESR2 mRNA were associated with poor prognosis for BCSS (log-rank test P ¼ .001 [ Figure 8B] Figure 10 , B and C, available online). Importantly, ESR2 expression levels per se did not appear substantially affected by TP53 status in the basal-like subgroup ( Figure 8C ).
The data from the METABRIC cohort was complemented with those from a small TNBC patient cohort (n ¼ 46) from Roswell. The patient tumors were stratified into high and low ESR2 as well as high and low TP53 expression based on median cut-off of continuous H-scoring. Because there was not sufficient tumor tissue available for sequencing TP53, intensity of IHC staining of TP53 was used as a surrogate for determining TP53 mutation status (78) (79) (80) . Tumors with mutant TP53 and higher levels of ESR2 were smaller in size and lower in stage (Supplementary Figure 10 , D and E, available online). Consistent with these data, TNBC patients with tumors with WT TP53 and high ESR2 levels had worse progression-free survival and overall survival (Supplementary Figure 10 , F and G, available online).
Discussion
Although bi-faceted functioning has been proposed to reconcile some of the disparate, complex, and often contradicting findings on ESR2 functions, the mechanistic basis for such duality has remained largely unknown. In this study, we discovered that TP53 status is an important determinant of pro-vs antiproliferative activity of ESR2 in BC cells. TP53 mutations have different clinical relevance depending on the subtypes of BC (6) . Clinical significance of our cellular and molecular data on TP53-dependent differential function of ESR2 is validated by our findings from the METABRIC TNBC patient cohort. In the mutant TP53-expressing basal-like tumors, those with high ESR2 levels have better survival. In the case of WT TP53-expressing tumors, those with high ESR2 levels were trending toward worse survival, although the difference was not statistically significant. Like most basal-like TNBC patient cohorts, only 16% of the METABRIC cohort was expressing WT p53, and a such low number of patients likely contributed to the statistically nonsignificant survival in this subcategory. Patient data from the Roswell cohort, although based on TP53 status determined by surrogate IHC staining, are consistent with those obtained from the much larger METABRIC cohort. These findings suggest that the ESR2-TP53 combination can be used to stratify TNBC into therapeutically actionable subgroups.
Our data show that treatment with tamoxifen can lead to sequestration of mutant TP53 away from TP73 and thereby reactivate tumor suppressor activities of TP73 provide, for the first time to our knowledge, a strong rationale for suggesting that tamoxifen therapy could be beneficial to basal-type and TNBC patients expressing mutant TP53. On the other hand, based on our data that ESR2 is pro-proliferative in the WT TP53 context, we predict that in TNBCs expressing WT TP53, tamoxifen or other agents that increase ESR2-WTP53 interaction may not only be ineffective as anti-tumor agents but also may contribute to adverse outcome.
There are limitations to our study. First, the unavailability of a sufficient number of basal-like TNBC patient cases with WT TP53 has hampered demonstration of a statistically significant difference in survival of this group based on ESR2 levels. Second, analysis of the role of ESR2 in ESR1 (ESR1)-expressing or ERþ tumors has proven to be much more complex, likely because of confounding effects of treatment with tamoxifen, which is standard-of-care for ERþ luminal BC. One might speculate that any effect of ESR2 in these tumors is potentially overcome by the strong positive response to tamoxifen therapy targeting ESR1, especially in the case of patients carrying WT TP53. These observations are consistent with our conclusion in this study that ESR2-TP53 interaction is likely to be more relevant in the case of TNBC.
In conclusion, our observations provide at least one explanation for the disparate reports on opposite functions of ESR2 in BC. These findings suggest that depending on the WT vs mutant TP53 status, downregulating or upregulating ESR2 alone as well as in combination with compounds capable of disrupting the WT TP53-ESR2 interaction or enhancing mutant TP53-ESR2 interaction could be promising therapeutic approaches. Most importantly, our findings on the novel effects of tamoxifen have important translational significance, especially because of the attractive prospect of relatively fast repurposing of tamoxifen for precision medicine to treat basal-like TNBC tumors stratified based on TP53 status.
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